Thus far, Pfizer's obesity efforts have crashed and burned. Last year, the pharmaceutical giant threw in the towel on ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines.

Pfizer surpasses Wall Street expectations with strong fourth-quarter earnings. Sustained demand for older drugs offsets ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired ...

Whereas conventional treatments such as chemotherapy and radiotherapy show their limitations in battling certain advanced ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer's fourth-quarter profits exceeded expectations, driven by strong demand for older drugs despite declining COVID-19 ...

NICE now recommends NHS use of the daily pill to patients with metastatic prostate cancer.